Promakhos Therapeutics
PrivateLast Round
Grant
May 6, 2026
Est. Valuation
$1.79M
Total Funding Raised
$794,365
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Promakhos Therapeutics is a biotechnology company developing advanced, targeted, immune-modulating therapies for autoimmune and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Promakhos Therapeutics Comparables
Compare Promakhos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Piton Therapeutics | 83% | |
| Ensho Therapeutics | 81% | |
| Eli Lilly and Company | 72% |
Promakhos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 6, 2026 | ||||
| Grant | Feb 19, 2024 | ||||
| Grant | Jan 24, 2024 | ||||
| Grant | Sep 1, 2023 | ||||
| Accelerator | Oct 31, 2021 | ||||
Accelerator | Jul 15, 2021 |
Key People
Founding team and executive leadership
Promakhos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pioneer Fund | Accelerator |
| Harvard Innovation Launch Lab | Seed |
| Harvard Innovation Labs | Accelerator, Seed |
| Metaplanet Holdings | Accelerator |
| ZAKA VC | Accelerator |
| Massachusetts Life Sciences Center | Grant |
| National Institute of Diabetes and Digestive and Kidney Diseases | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 6, 2026
$75K grant from Harvard President's Innovation Challenge.
- Feb 19, 2024
$100K grant from Massachusetts Life Sciences Center
Promakhos Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Promakhos Therapeutics's valuation, stock price, and market status.
Is Promakhos Therapeutics a public or private company?
Promakhos Therapeutics is a private company.
What is the current stock price of Promakhos Therapeutics?
Promakhos Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Promakhos Therapeutics worth (valuation)?
Promakhos Therapeutics's valuation is estimated at $1.8M based on funding round data.
Can I buy Promakhos Therapeutics stock?
Promakhos Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Promakhos Therapeutics's last funding round?
Promakhos Therapeutics's most recent funding round was Grant on July 15, 2021.
Who are the main investors in Promakhos Therapeutics?
Key investors in Promakhos Therapeutics include Harvard Innovation Labs.
Will Promakhos Therapeutics IPO soon?
No public IPO plans have been announced for Promakhos Therapeutics.
How can I track Promakhos Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Promakhos Therapeutics's secondary market activity and sign up for updates.